Results 41 to 50 of about 10,998 (173)

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (mRUNX1) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods Clinical and laboratory
Yi Han Xia, Eric McGinnis
wiley   +1 more source

Structure-activity relationship study of splicing modulators on Hsh155/SF3B1 through chemical synthesis and yeast genetics

Meayamycins are synthetic analogs of the natural product FR901464 and exhibit potent anticancer activity against human cancers. They bind SF3B1 and PHF5A, components of the human spliceosome, and alter pre-mRNA splicing.
John, Schmitz, Aaron, Hoskins, Jacob, Beard, Kazunori, Koide, Sierra, Love   +4 more
core   +1 more source

SF3B1: the lord of the rings in MDS [PDF]

Blood, 2020
Francesc Solé, Laura Palomo
openaire   +2 more sources

A highly abundant circular RNA from the RMST locus plays a role in posterior fossa ependymoma pathogenesis

Brain Pathology, Volume 36, Issue 4, July 2026.
circRMST (hsa_circ_0099634) is by far the most abundant isoform from the RMST locus. It is highly expressed in cancer cells throughout ependymoma patient samples and is located in the cytoplasm. circRMST knockdown causes cell cycle arrest and induces differentiation, and it is a marker for poor prognosis. The figure is made using BioRender.
Ulvi Ahmadov, Charlotte W. Udengaard, Stine M. Vissing, Silke D. Nielsen, Kim‐Gwendolyn Dietrich, Benedicte Parm Ulhøi, Lasse S. Kristensen   +6 more
wiley   +1 more source

Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
Integrated physical and virtual modeling provides a scalable framework to overcome sample scarcity, recapitulate mucosal melanoma biology, and accelerate translational discovery toward precision medicine. ABSTRACT Mucosal melanoma (MM) is a rare and lethal subtype of melanoma, disproportionately affecting Asian populations and exhibiting distinct ...
Xiangjie Jin, Yuhan Zhang, Yuantai Zhu, Zhiyuan Zhang, Chaoji Shi   +4 more
wiley   +1 more source

Ketogenic Diet as an Epigenetic Therapy in SETD1B‐Related Epilepsy

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1268-1275, June 2026.
ABSTRACT Histone lysine methyltransferases such as SETD1B regulate chromatin structure and gene transcription. Ketone bodies, including butyrate, act as histone deacetylase inhibitors. We report a 4‐year‐old boy with SETD1B‐related absence epilepsy, refractory to conventional medications, who achieved sustained > 90% seizure reduction on the Modified ...
Erica Tsang, Brian S. Gloss, Jessica P. Hayes, Andrew J. A. Holland, Manoj P. Menezes, Joceline A. Branson, Shekeeb S. Mohammad, Jingya J. Yan, Shrujna Patel, Velda X. Han, Russell C. Dale   +10 more
wiley   +1 more source

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex

American Journal of Hematology, Volume 101, Issue 6, Page 1407-1420, June 2026.
ABSTRACT The epidemiology of myelodysplastic syndromes/neoplasms (MDS) is challenging to define due to inconsistent reporting, complex diagnostic procedures, and evolving diagnostic criteria. Using the National MDS Natural History Study—a prospective cohort with centrally adjudicated histopathology and genetic variant review—we characterized the ...
Nancy Gillis, Christelle Colin‐Leitzinger, Yi‐Han Tang, Michael Otterstatter, Seth Sherman, Ling Zhang, Lynn C. Moscinski, Mary Ellen Walker, Jeffrey S. Painter, Gregory A. Abel, Tareq Al Baghdadi, H. Joachim Deeg, James M. Foran, Steven D. Gore, Alexandra M. Harrington, Steven H. Kroft, Jane Jijun Liu, Wael Saber, Shamsuddin Virani, Rafael Bejar, R. Coleman Lindsley, Eric Padron, Matthew J. Walter, Rami Komrokji, Amy E. DeZern, Mikkael A. Sekeres   +25 more
wiley   +1 more source

Genetic and Clinical Features in TP53‐Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next‐Generation Sequencing Data

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background The recent fifth edition of World Health Organization and International Consensus Classification in 2022 recognized TP53‐mutated myelodysplastic neoplasms (MDS) as a distinct entity requiring multi‐hit classification. Literatures indicate that TP53 variant alle frequency (VAF) correlates with clinical outcomes.
Yanming Cheng, Lixia Liu, Yu Gao, Yifei Wang, Wei Zhu, Hong Chen, Jiayue Qin, Yudi Zhang   +7 more
wiley   +1 more source

IGLV3‐21R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract IGLV3‐21R110 is a point mutation enabling autonomous B‐cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors.
Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Palash C. Maity, Armin Riecke, Christof Schneider, Billy M. C. Jebaraj, Rashmi P. Dheenadayalan, Hassan Jumaa, Marc Young, Manish Kumar, Lothar Müller, Ursula Vehling‐Kaiser, Michael Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna‐Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Petra Langerbeins, Eugen Tausch, Stephan Stilgenbauer   +24 more
wiley   +1 more source